DCE MRI for Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This clinical trial studies an imaging technique known as dynamic contrast enhanced magnetic resonance imaging (DCE MRI) in identifying the presence of pancreatic cancer. DCE MRI is a procedure that takes detailed pictures of functional and structural properties inside the body using magnetic field imaging. These images may better characterize pancreatic cancer in patients at high risk or in patients who may have undergone chemotherapy for pancreatic cancer.
Who Is on the Research Team?
Alexander Guimaraes
Principal Investigator
OHSU Knight Cancer Institute
Are You a Good Fit for This Trial?
This trial is for individuals at high risk of pancreatic cancer, those with confirmed pancreatic adenocarcinoma, and healthy volunteers without a history of cancer. Participants must be able to consent and women of childbearing potential need a negative pregnancy test. Exclusions include allergies to iron products, certain health conditions like hemochromatosis or renal insufficiency, HIV patients on specific treatments, and anyone unable to undergo MRI.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo DCE MRI to assess the presence and characteristics of pancreatic cancer
Treatment
Participants in Arm III may undergo chemotherapy prior to surgical resection
Follow-up
Participants are monitored for disease-free and overall survival
What Are the Treatments Tested in This Trial?
Interventions
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- Ferumoxytol
Dynamic Contrast-Enhanced Magnetic Resonance Imaging is already approved in United States, European Union for the following indications:
- Primary liver cancer (HCC)
- Metastatic colorectal cancer (liver metastases)
- Primary liver cancer (HCC)
- Metastatic colorectal cancer (liver metastases)
Find a Clinic Near You
Who Is Running the Clinical Trial?
OHSU Knight Cancer Institute
Lead Sponsor
National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Collaborator
National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
National Cancer Institute (NCI)
Collaborator
Oregon Health and Science University
Collaborator